Mumbai, Nov. 25 -- The therapies combine three proven medicines-Glycopyrronium, Formoterol, and Budesonide-to reduce airway obstruction, control inflammation, and improve lung function and symptom management. Designed as a single, easy-to-use nebulized therapy, the products aim to reduce the burden of multiple medications for patients.

Glenmark said the launch represents a breakthrough in COPD care, particularly benefiting patients who face challenges using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI). The company expects the therapy to set a new standard of care for managing COPD worldwide.

Alok Malik, president & business head, India Formulations, Glenmark Pharmaceuticals said, "At Glenmark, innovation is about reimagining...